Noteworthy Numbers

Web Exclusives - In the News

Thanks to medical research, there are nearly 12 million cancer survivors living in the United States today. And the research continues: There are approximately 400 new cancer therapies in preclinical and clinical development. As progress continues to treat those with cancer, let’s examine the statistics related to clinical trial participation.

From 1996 through 2002, National Cancer Institute (NCI)-sponsored cooperative group nonsurgical treatment trials for breast, colorectal, lung, and prostate cancers enrolled 75,215 patients:

  • 85.5% white
  • 9.2% black
  • 3.1% Hispanic
  • 1.9% Asian/Pacific Islander
  • 0.3% American Indian/Alaskan Native…

Cancer incidence was divided evenly among 3 participating age-groups (30-64, 65-74, ≥75 years) in the NCI-sponsored treatment trials; however, trial participant representation was heavily skewed toward the youngest age-group (68%).

Fewer than 5% of cancer patients participate in clinical trials… If 10% participated, studies potentially could be completed in 1 year, instead of the current 3 to 5 years.

Common cancer patient concerns regarding joining a clinical study include:

  • Fear of a reduction in quality of life
  • Reluctance to accept the possibility of receiving a placebo
  • Potential side effects
  • Treatments under study are not the best option.

Unfortunately, fewer than 4% of US physicians participate in clinical trials…

Therefore, although most trial participants are highly satisfied with their experience, 8 of 10 cancer patients may be unaware that a clinical trial was a possible option.

After identifying an appropriate trial, 40% of cancer patients either enroll or try to enroll…

Furthermore, most adult cancer patients who participate in clinical trials say a physician greatly influenced their decision to participate.

For those wishing to enroll, only 40% meet eligibility requirements and participate in clinical trials.

Most (91%) participants said they would recommend clinical trial participation to a friend or family member diagnosed with cancer.

Sources: The Center for Information & Study on Clinical Research Participation; National Cancer Institute.

Related Items
FDA News: July 2020
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Web Exclusives published on March 18, 2020 in In the News, Healthcare Policy
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Web Exclusives published on February 4, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Web Exclusives published on January 28, 2020 in FDA Updates, In the News, Sarcoma
Mixed Findings in Annual Cancer Statistics Report
Web Exclusives published on January 20, 2020 in In the News
FDA Grants Approval to Avapritinib for Patients with GIST
Web Exclusives published on January 13, 2020 in FDA Updates, Gastrointestinal Cancers, In the News, Rare Cancers
Recap of FDA Drug Approvals in 2019
Web Exclusives published on January 7, 2020 in FDA Updates, In the News
FDA Will Require Early Assessment of New Targeted Agents That May Be Used in Pediatric Cancers
Web Exclusives published on December 16, 2019 in In the News, Pediatric Cancer
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Web Exclusives published on December 11, 2019 in FDA Updates, In the News, Sarcoma
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
Web Exclusives published on November 25, 2019 in FDA Updates, In the News
Last modified: July 22, 2021